XLV — State Street Health Care Select
Is XLV overbought or oversold? Here is the current MarketMoodz read.
State Street Health Care Select (XLV) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The stock last closed at $187.88. The rating moved from Neutral to Overbought on November 14, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$187.88
- Last changeMoved from Neutral to Overbought on November 14, 2026
AI analysis
State Street Health Care Select (XLV) offers diversified, liquid exposure to the U.S. healthcare sector, combining defensive qualities with earnings-driven upside potential. Key threats include regulatory action, concentrated top holdings, and biotech-specific event risk; limited social and filing data increases short-term uncertainty.
Key factors
- Broad exposure to large-cap U.S. health-care names provides diversification across pharmaceuticals, biotech, medical devices and managed care
- Defensive sector characteristics historically help preserve value during market volatility and risk-off periods
- Recent market tone favors earnings-driven moves; healthcare earnings tend to be less cyclical than other sectors
- High liquidity and low tracking error typical of State Street ETFs support efficient trading and tight spreads
- Potential for positive flows into healthcare as investors seek growth-with-defense amid uncertain macro data
Risks
- Regulatory and policy risks (drug-pricing reforms, Medicare/Medicaid changes) can negatively impact constituent profitability
- Concentration risk in a handful of large-cap constituents could amplify idiosyncratic declines
- Biotech and pharma clinical-trial failures or patent cliff events can cause sudden downside
- Interest-rate and macro shifts that favor cyclicals or growth rotation away from defensives
- Limited social sentiment and fresh fundamental reporting in the provided data increases short-term uncertainty
Latest MarketMoodz coverage
- Costco Trade: Bull-Call Spread to Ride Market Rotation2026-06-23
- Rising Inflation Could Lift Value Stocks — IWD May Outperform2026-05-22
- Leerink Upgrades J&J on Icotyde, Inlexzo Pipeline Momentum2026-05-13
- FDA approves AbbVie/AstraZeneca CLL combo could set new standard2026-02-20
- Walmart Earnings Could Offer an Attractive Entry Point, Woods Says2026-02-17
See today's live rating, score and targets
Members see the live hourly rating for XLV — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.